CRO BioAgilytix and ATCC sign strategic partnership

By Melissa Fassbender contact

- Last updated on GMT

(Image: iStock/Tsyhun)
(Image: iStock/Tsyhun)

Related tags: Contract research organization, Biotechnology

ATCC has signed a strategic agreement with the contract research organization (CRO) BioAgilytix as part of its ongoing initiative to provide CRO services.

ATCC in recent years launched a new initiative to provide custom biological-based Contract Research Organization (CRO) services and standards for the life sciences community, with a focus on biotech and pharma​,” Scott Siegel, VP of Corporate Development and Chief Business Officer at ATCC, told Outsourcing-Pharma.com.

As part of this initiative, Siegel said the partnership with BioAgilytix represents “an important step forward.”

The agreement will span multi-year and involves a co-marketing arrangement across ATCC’s complementary areas of cell biology services.

Specifically, ATCC will offer tool and reagent development and storage services, including custom-engineered cell lines and primary cells to complement BioAgilytix’s assay solutions.

As a 90-year old life sciences institution, it is critical for ATCC to continuously seek ways to evolve and continue our mission of enabling important R&D activities that drive scientific discoveries and advancements​,” Siegel explained.

One of our strategic goals is to develop additional scientifically-relevant products and services, and key to that goal is the expansion of our custom biological-based Contract Research Organization (CRO) services and standards​,” he added.

With this goal in mind, the company evaluated external opportunities in the bioanalytical space and chose BioAgilytix as a partner.

Through the strategic partnership, Seigel explained the companies’ complementary capabilities provide the market with “a total assay solution​” to facilitate “the rapid and efficient development of important new medicines​.”

Additionally, a minority equity investment on the part of ATCC signals the company’s commitment to the relationship and provides the company with a seat on BioAgilytix’s commercial advisory board.

Now that the agreement is signed, Siegel said ATCC is planning a kick-off meeting with BioAgilityix to begin implementing co-marketing plans.

Related topics: Preclinical Research

Related news

Show more

Follow us

Featured Events

View more

Products

View more

Webinars